IDH1 mutation, olutasidenib, refractory acute myeloid leukemia, Rezlidhia
Olutasidenib is approved by FDA for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation
Dec 2022: Olutasidenib (Rezlidhia) capsules were approved by the Food and Drug Administration (FDA) for adult patients with relapsed or resistant acute myeloid leukaemia (AML) who have a susceptible IDH1 mutation as identifie..